If you’re anything like me, what finally made you stop rolling your eyes at the term “artificial intelligence” was OpenAI’s ...

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...

Q1 2025 Management View Sean McClain, Founder and CEO, announced "Today marks a significant milestone for Absci. We have ...

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the ...

Absci also release first quarter results after the close. The company posted a loss of $26.3 million, or 21 cents a share, compared with a loss of $22 million, or 22 cents a share, a year earlier.

Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative ...

Thank you for standing by, and welcome to Absci first quarter 2025 business update and financial and operating results conference call. (Operator Instructions) I would now like to hand the call over ...

Across the recent three months, 6 analysts have shared their insights on Absci (NASDAQ:ABSI), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Sean McClain, Founder and CEO, announced "Today marks a significant milestone for Absci. We have initiated our first-in-human clinical trial for ABS-101, officially making Absci a clinical stage ...